Richard J. Sylvester

Richard J. Sylvester's AcademicInfluence.com Rankings

Mathematics

#5446

World Rank

#7663

Historical Rank

Statistics

#371

World Rank

#439

Historical Rank

Measure Theory

#732

World Rank

#987

Historical Rank

mathematics Degrees

Download Badge

Mathematics

Why Is Richard J. Sylvester Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Richard J. Sylvester's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. (2002) (3019)
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. (2006) (2530)
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. (2013) (1985)
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. (2017) (1867)
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial (2001) (1298)
International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers (1997) (1180)
Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. (2002) (1157)
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis (2006) (1005)
Long-Term Results of a Randomized Trial Comparing Breast-Conserving Therapy With Mastectomy: European Organization for Research and Treatment of Cancer 10801 Trial (2000) (914)
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. (2019) (848)
Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. (2005) (805)
Prognostic factors for survival in adult patients with cerebral low-grade glioma. (2002) (804)
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. (2008) (791)
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials (2000) (784)
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data (1997) (748)
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. (2015) (744)
A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. (2011) (717)
A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. (2004) (655)
A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. (2007) (653)
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. (2011) (627)
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. (2009) (618)
Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. (2002) (599)
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. (2012) (568)
Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. (2001) (567)
A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. (1979) (543)
International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. (2011) (528)
Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. (2001) (501)
Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853 (2000) (499)
Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial. (1992) (444)
European guidelines on upper tract urothelial carcinomas: 2013 update. (2013) (433)
Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. (2014) (427)
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. (2012) (423)
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. (2001) (422)
Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. (2005) (420)
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. (2016) (419)
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. (2015) (404)
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. (2020) (402)
Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. (2013) (398)
A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. (1993) (363)
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. (2000) (352)
An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. (2009) (327)
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. (1997) (326)
Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. (2005) (323)
Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladd (2010) (312)
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. (2015) (308)
[EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update]. (2012) (295)
European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. (2011) (292)
A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer (1996) (292)
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). (2021) (291)
Factors affecting recurrence and progression in superficial bladder tumours. (1995) (290)
What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. (2017) (289)
Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from (2016) (277)
Factors influencing local relapse and survival and results of salvage treatment after breast-conserving therapy in operable breast cancer: EORTC trial 10801, breast conservation compared with mastectomy in TNM stage I and II breast cancer. (1992) (274)
An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. (1998) (265)
Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. (2009) (264)
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. (2015) (263)
Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. (2016) (257)
Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. (1993) (257)
Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. (2003) (253)
An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. (1998) (253)
Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. (1999) (235)
EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma. (2004) (232)
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. (1997) (227)
Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. (1987) (226)
Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. (2015) (224)
Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. (2012) (218)
Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group. (1999) (212)
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. (2005) (211)
Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. (2015) (207)
Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. (2018) (189)
The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. (2010) (189)
Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. E (1995) (188)
Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. (2016) (181)
The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. (2008) (181)
Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. (1998) (177)
Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. (1986) (177)
Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. (2017) (173)
Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group. (1983) (169)
Maximal Androgen Blockade: Final Analysis of EORTC Phase III Trial 30853 (1998) (166)
"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). (1991) (165)
Significance of Bladder Biopsies in Ta,T1 Bladder Tumors: A Report from the EORTC Genito-Urinary Tract Cancer Cooperative Group (1999) (159)
Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1 and CIS) (2014) (153)
Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986. (2009) (151)
Radical Nephrectomy with and without Lymph Node Dissection: Preliminary Results of the EORTC Randomized Phase III Protocol 30881 (1999) (151)
Cancer Clinical Trials: Methods and Practice. (1985) (145)
Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. (2001) (137)
European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. (2021) (136)
Significance of quantitative assessment of estrogen receptors for endocrine therapy in advanced breast cancer (1977) (135)
Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. (1998) (134)
Treatment of Superficial Bladder Tumors: Achievements and Needs (2000) (132)
One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? (2004) (128)
The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. (2000) (123)
EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. (2005) (121)
Cyvadic in advanced soft tissue sarcoma: A randomized study comparing two schedules: A study of the EORTC soft tissue and bone sarcoma group (1984) (120)
Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer (1980) (117)
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial (2010) (110)
Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. (1987) (110)
The impact of re‐transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high‐grade/Grade 3 bladder cancer treated with bacille Calmette–Guérin (2016) (110)
Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer (2004) (109)
The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. (2000) (108)
Multicollinearity in prognostic factor analyses using the EORTC QLQ‐C30: identification and impact on model selection (2002) (108)
Grading of Urothelial Carcinoma and The New "World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016". (2018) (106)
European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas, 2011 update (2012) (105)
High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group. (1991) (105)
Prognostic factors in bladder carcinoma: Histologic parameters and expression of a cell cycle‐related nuclear antigen (Ki‐67) (1992) (105)
Hyperfractionated or accelerated radiotherapy for head and neck cancer. (2010) (104)
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. (2005) (104)
Key Steps in Conducting Systematic Reviews for Underpinning Clinical Practice Guidelines: Methodology of the European Association of Urology. (2018) (104)
Grading of soft tissue sarcomas: experience of the EORTC Soft Tissue and Bone Sarcoma Group. (1993) (101)
The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. (1995) (100)
Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review. (2017) (100)
Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials. (1989) (99)
Long-Term Follow-Up of an EORTC Randomized Prospective Trial Comparing Intravesical Bacille Calmette-Guerin-RIVM and Mitomycin C in Superficial Bladder Cancer (1999) (94)
Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). (2005) (93)
Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC Breast Cancer Co-operative Group Trial (10792). (1989) (92)
Natural History, Recurrence, and Progression in Superficial Bladder Cancer (2006) (89)
Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. (1995) (88)
Intravesical BCG in Patients with Carcinoma in situ of the Urinary Bladder: Long–Term Results of EORTC GU Group Phase II Protocol 30861 (2001) (88)
Bacillus Calmette–Guérin treatment of non‐muscle invasive bladder cancer (2011) (87)
Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911. (1997) (85)
Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer. (2012) (84)
Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer Randomized Phase III Trial. (1997) (83)
Identifying the types of missingness in quality of life data from clinical trials. (1998) (83)
Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma. (2013) (80)
Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone. (1982) (79)
Some Limitations of the Radioisotope Bone Scan in Patients With Metastatic Prostatic Cancer (1990) (78)
Prostatic Specific Antigen and the Prediction of Prognosis in Metastatic Prostatic Cancer (1990) (78)
Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. (2013) (73)
The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. (2014) (73)
EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group. (1995) (73)
What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Gu (2019) (72)
The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder. (2001) (71)
Reply to Anna Orsola, Lluís Cecchini and Juan Morote's Letter to the Editor re: Marko Babjuk, Willem Oosterlinck, Richard Sylvester, et al. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder. Eur Urol 2008;54:303–14 (2009) (71)
The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. (2003) (70)
Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. (2020) (69)
Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study. (1987) (69)
Quality of institutional participation in multicenter clinical trials. (1981) (69)
Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. (1997) (68)
Guidelines on Non-muscle invasive Bladder Cancer (2013) (67)
A bayesian approach to the design of phase II clinical trials. (1988) (67)
Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906). (2005) (63)
Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guérin. (2015) (63)
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. (2001) (62)
The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. (2016) (60)
The shared frailty model and the power for heterogeneity tests in multicenter trials (2002) (60)
Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. (1993) (59)
Guidelines on TaT 1 ( Non-muscle invasive ) Bladder Cancer (2006) (59)
Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. (2017) (58)
Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group. (1996) (56)
Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group. (1998) (53)
Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cance (1992) (52)
Identifying patients with a high risk of relapse in quiescent Crohn's disease. The GETAID Group. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. (1995) (52)
Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group. (1995) (52)
A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. (2000) (52)
Prognostic factors in superficial bladder tumors (1992) (52)
Frailty modelling for survival data from multi‐centre clinical trials (2011) (51)
Kidney Cancer A Prospective Randomized EORTC Intergroup Phase 3 Study Comparing the Complications of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma (2007) (50)
High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. (1986) (49)
Individual patient-versus literature-based meta-analysis of survival data: time to event and event rate at a particular time can make a difference, an example based on head and neck cancer. (2001) (49)
478 One immediate postoperative instillation of chemotherapy reduces the risk of recurrence in patients with stage TA T1 bladder cancer: A meta-analysis of the published results of randomized clinical trials (2004) (49)
Carminomycin vs adriamycin in advanced soft tissue sarcomas: an EORTC randomised phase II study. (1983) (48)
Reply to Harry Herr's Letter to the Editor re: Marko Babjuk, Andreas Böhle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447-61. (2017) (47)
Phase II trials in Ta, T1 bladder cancer. The marker tumour concept. (1996) (47)
Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. (1998) (47)
Zoladex and Flutamide Versus Bilateral Orchiectomy (1990) (46)
Liposomal Nystatin in Patients with Invasive Aspergillosis Refractory to or Intolerant of Amphotericin B (2004) (44)
The Importance of Prognostic Factors in the Interpretation of Two EORTC Metastatic Prostate Cancer Trials (1998) (43)
Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen. (1985) (40)
Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993). (2011) (40)
Maximum Androgen Blockade Using LHRH Agonist Buserelin in Combination with Short-Term (Two Weeks) or Long-Term (Continuous) Cyproterone Acetate Is Not Superior to Standard Androgen Deprivation in the Treatment of Advanced Prostate Cancer (1998) (40)
Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group. (1995) (40)
Conventional vs modified fractionated radiotherapy. meta-analysis of radiotherapy in head & neck squamous cell carcinoma : a meta-analysis based on individual patient data (2002) (40)
The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use. (2015) (39)
A Bayesian approach to jointly estimate centre and treatment by centre heterogeneity in a proportional hazards model (2005) (39)
Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer (2014) (39)
Bladder Cancer Predicting Recurrence and Progression in Individual Patients with Stage Ta T 1 Bladder Cancer Using EORTC Risk Tables : A Combined Analysis of 2596 Patients from Seven EORTC Trials (2006) (39)
How well can you actually predict which non-muscle-invasive bladder cancer patients will progress? (2011) (39)
A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials. (2009) (38)
Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer (1999) (38)
Phase II study of cisplatin in advanced osteogenic sarcoma. European Organization for Research on Treatment of Cancer Soft Tissue and Bone Sarcoma Group. (1985) (38)
Overview of randomized perioperative polychemotherapy trials in women with early-stage breast cancer. (1997) (38)
A European Organization for Research and Treatment of Cancer--Genitourinary Group phase 2 study of chemotherapy in stage T3-4N0-XM0 transitional cell cancer of the bladder: evaluation of clinical response. (1992) (37)
In vitro estimate of sensitivity of individual human tumors to antitumor agents. (1974) (37)
Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897). (1996) (37)
TNM classification of genitourinary tumours 1987--position of the EORTC Genitourinary Group. (1988) (37)
An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis. (2004) (35)
Zoladex and Flutamide Versus Orchiectomy in the Treatment of Advanced Prostatic Cancer (1990) (35)
Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group. (2006) (34)
Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences * (2001) (33)
A combined analysis of EORTC/MRC randomized clinical trials for the prophylactic treatment of TaT1 bladder cancer. Eortc Genito-Urinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. (1996) (33)
Using the continual reassessment method: lessons learned from an EORTC phase I dose finding study. (2006) (32)
Cancer clinical trials : methods and practice (1986) (31)
Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. (2021) (31)
Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery (1991) (31)
Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought (2018) (31)
Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer. (1997) (30)
Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865). (1993) (30)
Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group. (1992) (30)
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. (2012) (30)
Relation between estrogen receptor concentration and clinical and histological factors: their relative prognostic importance after radical mastectomy for primary breast cancer. (1989) (29)
CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial. (1980) (29)
Using permutation tests and bootstrap confidence limits to analyze repeated events data from clinical trials. (1989) (26)
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†. (2015) (26)
Guidelines on Urothelial Carcinomas of the Upper Urinary Tract (2013) (26)
Doxorubicin in relapsed soft tissue sarcoma: justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group Study. (1990) (26)
Orchidectomy versus buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843 (1990) (26)
Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. (2020) (25)
Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: a double-blind randomized study. European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group. (1993) (25)
European Experience of Adjuvant Chemotherapy for Soft Tissue Sarcoma: Interim Report of a Randomized Trial of Cyvadic Versus Control (1988) (25)
Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. (2020) (25)
Variable selection in subdistribution hazard frailty models with competing risks data (2014) (25)
Conflict of Evidence: Resolving Discrepancies When Findings from Randomized Controlled Trials and Meta-analyses Disagree. (2017) (24)
Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial. (1999) (24)
Prognost ic Factors for Surv iva l in Adul t Pat ients With Cerebral Low-Grade Gl ioma (2002) (24)
E.O.R.T.C. phase II study of cisplatin in cyvadic-resistant soft tissue sarcoma. (1979) (23)
Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853) (1993) (22)
Statistical tables for the design of clinical trials: David machin and michael campbell lackwell scientific publications, Oxford, 1987, 210 pp., $54.00 (1988) (22)
A decision theory approach to phase II clinical trials. (1977) (22)
Frequency of Positive Biopsies after Visual Disappearance of Superficial Bladder Cancer Marker Lesions (2001) (22)
Bacillus Calmette-Guérin versus mitomycin intravesical therapy in superficial bladder cancer (1992) (21)
Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019? (2019) (21)
The International Bladder Cancer Bank: proposal for a new study concept. (2004) (21)
Maintenance bacillus calmette-guerin for TA, T1 bladder cancer is not associated with increased toxicity, results from an eortc genito-urinary group phase III trial (2003) (21)
Marker tumour response to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours (1996) (20)
Objective response of superficial bladder tumors to intravesical treatment (including review of response of marker lesions). (1992) (20)
920: Bacillus Calmette-Guerin Versus Chemotherapy in the Intravesical Treatment of Carcinoma in Situ: A Meta-Analysis of the Published Results of Randomized Clinical Trials (2005) (20)
Statistical analysis techniques and sample size determination for clinical trials of treatments for bladder cancer. (1986) (20)
Total androgen ablation: European experience. The EORTC GU Group. (1991) (19)
Assessing the quality of studies on the diagnostic accuracy of tumor markers. (2014) (19)
Final results of EORTC intergroup randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder. (2014) (19)
Treatment outcome studies. pitfalls in current methods and practice. (2002) (19)
Importance of bleomycin in combination chemotherapy for good prognosis testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group (1997) (18)
Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow‐up of non‐muscle‐invasive bladder cancer: a blinded prospective multicentric study (2020) (18)
European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer. (1987) (18)
Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group. (1990) (18)
[EAU guidelines on non-muscle-carcinoma of the bladder]. (2009) (18)
Adjuvant therapy of T1 bladder carcinoma: preliminary results of an EORTC randomized study. (1978) (18)
Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized EORTC study of CMF vs CMF + tamoxifen. (1985) (18)
A new standard treatment for advanced premenopausal breast cancer: A meta-analysis of the Combined Hormonal Agent Trialists Group (CHAT) (1998) (17)
Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Non Muscle Invasive Bladder Cancer Follow up: A Blinded, Prospective Cohort, Multicentric European Study. (2020) (17)
Orchidectomy versus Zoladex® plus Eulexin® in patients with metastatic prostate cancer (EORTC 30853) (1990) (17)
Prognostic Factors in Non–Muscle-Invasive Bladder Tumors: I. Clinical Prognostic Factors: A Review of the Experience of the EORTC Genito-Urinary Group II. Biologic Prognostic Markers (2007) (17)
Short‐term versus long‐term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer (1993) (17)
Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin-based chemotherapy (CHT): Phase III results of EORTC study 30986. (2010) (17)
WHO handbook for reporting results of cancer treatment: WHO offset publication #48 World Health Organization, Geneva, 1979, 45 pages, 6 Swiss Francs☆ (1980) (16)
Inhibition of DNA polymerases and neoplastic cells by selected SH inhibitors. (1972) (16)
Intracavitary treatment of transitional cell carcinoma of the bladder: questions and lessons after 27 years of experience. (1989) (16)
Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin. (2021) (16)
Statistical methodology of phase III cancer clinical trials: advances and future perspectives. (2002) (15)
Mitomycin C (MCC) in advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. (1985) (15)
Comparison of the effects of high dose estramustine phosphate and mitomycin C on the time to progression and length of survival of patients with progressive, advanced endocrine-independent prostatic cancer: An interim analysis of EORTC-GU group study no. 30865 (1990) (15)
LONG-TERM EFFICACY RESULTS OF EORTC GU GROUP STUDY 30911 COMPARING EPIRUBICIN, BACILLUS CALMETTEGUERIN (BCG), AND BCG PLUS ISONIAZID IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STAGE TA T1 PAPILLARY CARCINOMA OF THE BLADDER (2008) (15)
Thoughts on a systematic review and meta-analysis of adjuvant chemotherapy in muscle-invasive bladder cancer. (2014) (15)
The role of meta-analyses in assessing cancer treatments. (2000) (15)
Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: a joint European Organization for Research and Treatment of Cancer-Dutch Breast Cancer Working Party Study. Cooperating Investigators. (1995) (15)
A plea for cold biopsy, fulguration and immediate bladder instillation with Epirubicin in small superficial bladder tumors. Data from the EORTC GU Group Study 30863. (1993) (15)
Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas (2004) (14)
Concepts for banking tissue in urologic oncology--the International Bladder Cancer Bank. (2005) (14)
Heterogeneity in disease free survival between centers: lessons learned from an EORTC breast cancer trial (2006) (14)
Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy (2018) (14)
EORTC protocols in prostatic cancer. An interim report. (1980) (14)
A reversal of fortune: practical problems in the monitoring and interpretation of an EORTC breast cancer trial. (1994) (14)
Analysing longitudinal continuous quality of life data with dropout (2002) (13)
Diagnostic performance of image technique based transurethral resection for non-muscle invasive bladder cancer: systematic review and diagnostic meta-analysis (2019) (13)
Bacillus Calmette-Guérin versus mitomycin C for the treatment of intermediate-risk non-muscle-invasive bladder cancer: the debate continues. (2009) (13)
An immediate instillation after transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: has the evidence changed? (2009) (13)
Prognostic factors in metastatic non-seminomatous germ cell tumours: an interim analysis of the EORTC GU-Group experience. (1993) (13)
Sample size estimation in phase III cancer clinical trials. (1999) (13)
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer. (2021) (13)
A phase II study of 4-epi-adriamycin in advanced urothelial transitional cell cancer. EORTC-GU Group protocol 30867. (1989) (13)
Evaluation of adjuvant therapy in soft tissue sarcoma. A collaborative multidisciplinary approach. E.O.R.T.C. protocol 62771. (1979) (12)
Statistics with confidence: Confidence intervals and statistical guidelines. Martin J. Gardner and Douglas G. Altman (eds), British medical journal, London, 1989. no. of pages: 140. price: £7.95 ($19.00) (1990) (12)
Radical nephrectomy with and without lymph node dissection: preliminary results of EORTC Protocol 30881. The EORTC Genitourinary Group. (1992) (12)
Validation of prognostic indices using the frailty model (2009) (12)
Mitoxantrone in advanced bladder carcinoma. A phase II study of the EORTC Genito-urinary Tract Cancer Cooperative Group. (1985) (12)
Multivariate analysis of prognostic variables in patients with disseminated non-seminomatous testicular cancer: results from an EORTC multi-institutional phase III study. (1987) (12)
EORTC randomized trial for the adjuvant therapy of T1 bladder carcinoma. (1976) (12)
Mitoxantrone in advanced renal cancer: a phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group. (1984) (11)
Long-term follow-up in superficial transitional cell carcinoma of the bladder: prognostic factors for time to first recurrence, recurrence rate, and survival. Final results of a randomized trial comparing doxorubicin hydrochloride, ethoglucid, and transurethral resection alone. EORTC Genitourinary T (1989) (11)
Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa – pT 1 Urothelial Carcinoma of the Bladder : Which Patients Benefit from the Instillation ? (2015) (11)
On the analysis of response rates in studies of advanced disease. (1980) (11)
Intravesical chemotherapy in non-muscle-invasive bladder cancer: what schedule and duration of treatment? (2007) (11)
The natural history and the prognosis of treated superficial bladder cancer. EORTC GU Group. (1992) (11)
Should all patients receive an immediate chemotherapeutic drug instillation after resection of papillary bladder tumors? (2011) (11)
BCG Immunotherapy for Superficial Bladder Cancer: An Overview of the Past, the Present and the Future (2003) (11)
Estramustine phosphate in prostate cancer (1984) (11)
Diagnostic accuracy of photodynamic diagnosis with 5-aminolevulinic acid, hexaminolevulinate and narrow band imaging for non-muscle invasive bladder cancer (2020) (10)
The use of selected sulfhydryl inhibitors in a preferential drug attack on cancer. (1971) (10)
E.O.R.T.C. protocol for the therapy of metastatic soft tissue sarcoma, a randomized trial. (1977) (10)
Hyperfractionated and/or accelerated radiotherapy versus conventional radiotherapy for head and neck cancer (2000) (10)
Final results from an EORTC (GU Group)/NCRI randomized phase III trial of adjuvant interleukin-2, interferon alpha, and 5-fluorouracil in patients with a high risk of relapse after nephrectomy for renal cell carcinoma (RCC). (2011) (10)
Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group) (1991) (10)
Combining a molecular profile with a clinical and pathological profile: Biostatistical considerations (2008) (10)
Can radical prostatectomy benefit patients despite the presence of regional metastases? (2010) (10)
Low-dose fortnightly methotrexate in advanced prostate cancer. The EORTC Genito-Urinary Tract Cancer Cooperative Group. (1990) (10)
[European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. European Association of Urology Guideline Group for urothelial cell carcinoma of the upper urinary tract]. (2012) (10)
Exploratory Subgroup Analyses of Renal Function and Overall Survival in European Organization for Research and Treatment of Cancer randomized trial of Nephron-sparing Surgery Versus Radical Nephrectomy. (2017) (10)
The analysis of results in prophylactic superficial bladder cancer studies. (1985) (10)
NMIBC risk calculators: how useful are they for the practicing urologist and how can their clinical utility be improved? (2013) (10)
Tryptophan Metabolites, Pyridoxine (Vitamin B(6)) and Their Influence on the Recurrence Rate of Superficial Bladder Cancer (1995) (10)
Guidelines for the preparation of E.R.T.C. cancer clinical trial protocols. (1980) (9)
Non-muscle-invasive Bladder Cancer ( TaT 1 and CIS ) EAU Guidelines on (2016) (9)
EORTC Protocol 30853: Orchidectomy Versus Zoladex Plus Flutamide in the Management of Metastatic Carcinoma of the Prostate (1990) (9)
Analysis and presentation (1997) (9)
Change in white cell count during treatment of advanced cancer of the prostate with estramustine phosphate and with stilboestrol. (1983) (9)
What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis (2018) (9)
1050 Bacillus Calmette-Guerin: One third dose versus full dose and one year versus three years of maintenance. Final results of an EORTC GU Cancers Group randomized trial in non muscle invasive bladder cancer (2012) (9)
Editorial comment on: prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. (2008) (8)
A multivariate analysis of prognostic factors in disseminated non-seminomatous testicular cancer. (1988) (8)
Key steps in conducting systematic reviews for underpinning clinical practice guidelines: Methodology of the European Association of Urology (2018) (8)
A comparison of the alternative methods of calculating survival curves arising from clinical trials. (1978) (8)
N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group. (1982) (8)
Complete androgen blockade: data from an EORTC 30853 trial. (1990) (7)
3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin Plus Isoniazid in Patients With Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder (2010) (7)
Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urin (1998) (7)
Alternating cyclical hormonal-cytotoxic combination chemotherapy in postmenopausal patients with breast cancer. An EORTC trial. (1980) (7)
Potential benefit of lymph node dissection during radical nephroureterectomy for upper tract urothelial carcinoma: A systematic review by the European Association of Urology Guidelines Panel on non-muscle-invasive bladder cancer (2018) (7)
Treatment of advanced soft tissue sarcoma with chlorozotocin: a phase II trial of the EORTC soft tissue and bone sarcoma group. (1981) (7)
Mitomycin-C in the treatment of metastatic prostate cancer: report on an EORTC phase II study (1986) (7)
Current status of intravesical chemotherapy trials in the EORTC Urological Group. An Overview (2004) (7)
Design of phase II clinical trials in cancer using decision theory. (1980) (7)
Chemotherapy with estrogenic recruitment in breast cancer: experimental and clinical studies. (1985) (7)
Carminomycin versus doxorubicin in advanced breast cancer, a randomized phase II study of the E.O.R.T.C. Breast Cancer Cooperative Group. (1986) (7)
EORTC Group Study 30851: a phase II study of neoadjuvant chemotherapy in patients with invasive bladder cancer. (1990) (7)
Adjuvant chemotherapy of superficial transitional cell carcinoma: an E.O.R.T.C. randomized trail comparing doxorubicin hydrochloride, ethoglucid and TUR-alone. (1985) (7)
Activities of the EORTC Breast Cancer Co-operative Group: an overview. [European Organization for Research and Treatment of Cancer]. (1988) (7)
Estrogen receptor variations in neoplastic tissue during the course of disease in patients with recurrent breast cancer. (1984) (6)
Neoadjuvant chemotherapy for invasive bladder cancer (2005) (6)
Statistical methodology for personalized medicine: New developments at EORTC Headquarters since the turn of the 21st Century (2012) (6)
Preliminary results from a randomized phase III trial of adjuvant interleukin-2, interferon alpha and 5-fluorouracil in patients with a high risk of relapse after nephrectomy for renal cell carcinoma (RCC) (2008) (6)
651 IMMUNOTHERAPY OR CHEMOTHERAPY AS LOCAL THERAPY OF URINARY BLADDER CANCER – WHICH IS THE MOST EFFECTIVE? REPORT ON A META-ANALYSIS OF THE LONG-TERM OUTCOME OF RANDOMIZED STUDIES COMPARING INTRAVESICAL MITOMYCIN C VERSUS BACILLUS CALMETTE-GUERIN FOR NON-MUSCLE INVASIVE BLADDER CANCER (2009) (6)
An overview of the EORTC Breast Cancer Cooperative Group's activities. (1983) (6)
Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered? (2018) (6)
Systemic humoral responses of non-muscle-invasive bladder cancer during BCG treatment: less is more (2017) (6)
Comparability of prostate trials (1993) (6)
Phase II trial of methylene dimethane sulphonate (MDMS) in advanced soft tissue sarcomas of the adult. A study of the EORTC Soft Tissue and Bone Sarcoma Group. (1989) (6)
Maintenance Bacillus Calmette-Guérin Therapy: The Search for the Optimum Treatment Schedule Continues. (2015) (5)
Can the primary tumour be used as the sole parameter for response in phase II chemotherapy studies in metastatic prostate cancer? An EORTC Genito-Urinary Group Report (1986) (5)
Reply to G. Sonpavde et al (2010) (5)
Re: Shahrokh F. Shariat, Behfar Ehdaie, Michael Rink, et al. Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur urol 2012;61:237-42. (2012) (5)
The value of the bone scan. (1990) (5)
Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: Preliminary results of a double-blind randomized study of the eortic breast cancer cooperative group (1990) (5)
A phase II study of M-azido-pyrimethamine ethane sulphonate (MZPES) in advanced, recurrent soft tissue sarcoma. An EORTC Soft Tissue and Bone Sarcoma Group Study. (1989) (5)
A randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs. estramustine alone in patients with hormone escaped progressive metastatic prostate cancer (1998) (5)
Time-dependent prognostic factors in advanced prostatic cancer. (1990) (5)
Zoladex and flutamide vs orchidectomy: a phase III EORTC 30853 trial. EORTC Urological Group. (1989) (5)
The role of radiotherapy in breast conserving treatment of ductal carcinoma in situ (DCIS): First results of EORTC trial 10853 (1998) (5)
Phase II study of low-dose methotrexate in advanced osteosarcoma followed by escalation after disease progression: a study of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research on Treatment of Cancer. (1986) (5)
Prognostic factors for randomization and stratification and endpoints for the evaluation of trials. (1988) (5)
Phase II study of anhydro-ara-5-fluorocytidine in adenocarcinoma of gastrointestinal tract, epidermoid carcinoma of lung, head and neck, breast carcinoma and small cell anaplastic carcinoma of lung. A study report of the E.O.R.T.C. early clinical trial cooperative group. (1978) (4)
834: Predicting Recurrence and Progression in Stage TA T1 Bladder Cancer Patients Using Eortc Risk Tables (2006) (4)
Is overall survival not influenced by partial vs radical nephrectomy? (2018) (4)
Update of EORTC clinical trials in prostate cancer. The EORTC Genito-Urinary Group. (1992) (4)
Chemotherapy in Advanced Soft Tissue Sarcoma — The EORTC Experience (1988) (4)
EORTC protocol for therapy of metastatic soft tissue sarcomas, a randomized trial (1977) (4)
Cooperative studies of systemic chemotherapy (1983) (4)
Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non-muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker. (2022) (4)
Preliminary Results of Two Eortc Randomized Trials in Previously Untreated Patients with Advanced T3 — T4 Prostatic Cancer (1983) (4)
Selected sulfhydryl inhibitors capable of inducing immunity against cancer in mice. (1979) (4)
Only an overall 15% net benefit emerges in favour of adjuvant intravesical chemotherapy when compared to transurethral resection alone for the prevention of recurrences of superficial bladder tumors. (2006) (4)
Mitozolomide in advanced renal cancer (1989) (4)
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer (2021) (4)
Does the treating institution have an impact on the overall and failure-free survival of patients with 'poor prognosis' metastatic non-seminomatous germ cell tumours? (1998) (4)
The use of intravesical chemotherapy and possibilities for improving its efficacy. (2006) (4)
Original Articles: Bladder Cancer (1995) (4)
658 PROGNOSTIC FACTORS FOR RECURRENCE AND PROGRESSION IN T1G3 BLADDER CANCER TREATED WITH BCG: CIS IN THE PROSTATIC URETHRA AND GENDER (2009) (4)
Chemotherapy with estrogenic recruitment in breast cancer : Experimental background and clinical studies conducted by the EORTC breast cancer cooperative group (1986) (4)
Rational chemotherapy: inhibition of polymerase activity of cancer cells. (1973) (4)
Cyproterone acetate versus medroxyprogesterone acetate versus diethylstilbestrol in the treatment of prostate cancer: results from EORTC Study 30761. (1987) (4)
EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group. (1989) (4)
Letters to the Editor/ErrataRE: A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALS (2005) (4)
BCG treatment in Tis of the urinary bladder, results of the EORTC Protocol 30861. EORTC GU Group. (1992) (3)
Hyperfractioned or accelerated radiotherapy in head and neck cancer: a meta‐analysis (2007) (3)
The side effects of bacillus calmette-guerin in the treatment of TA Ti bladder cancer do not predict its efficacy: Results from an eortic genito-urinary group phase III trial (2003) (3)
Contribution of Estrogen Receptors to the Strategy of Breast Cancer Treatment (1981) (3)
The Clinical Value of the Serum Acid Phosphatase in Carcinoma of the Prostate (1983) (3)
280 Results of the randomized trial comparing radical and partial nephrectomy for small kidney neoplasms eortc protocol 30904 (2004) (3)
RELATIONSHIP BETWEEN EFFICACY AND SIDE EFFECTS OF BCG INSTILLATIONS IN TA - T1 BLADDER CANCER: RESULTS OF EORTC TRIAL 30911 (1999) (3)
Chemohyperthermia with Mitomycin-C Compared with Bacillus Calmette-Guérin: A "Hot" Topic. (2016) (3)
A PHASE II STUDY OF THE ABLATIVE EFFECT OF QUARTER DOSE BCG ON A PAPILLARY MARKER LESION OF THE BLADDER (1999) (3)
Hormone therapy in prostatic cancer. (1980) (3)
Comparability of EORTC and DAPROCA Studies in Advanced Prostatic Cancer (1990) (3)
1001 The impact of re-TUR on clinical outcomes in a large cohort of t1g3 patients treated with BCG (2014) (3)
The significance of bladder biopsies in TA, T1 bladder tumors Report from the EORTC-GU Group (1997) (3)
Ascorbic acid as a thiolprive: ability to induce immunity against some cancers in mice. (1981) (3)
Does isoniazed reduce side effects of intravesical Bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of EORTC protocol 30911 (1997) (3)
Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease (2017) (3)
Influence of postoperative radiotherapy on local recurrence and survival of bronchial epidermoid carcinoma with regard to nodal status: preliminary results of the EORTC protocol 08741. (1978) (3)
Randomized phase II/III trial assessing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) "unfit" for cisplatin based chemotherapy (CHT): Updated phase II results and risk group analysis of EORTC study 30986 (2008) (3)
European Association of Urology Guidelines Office: How We Ensure Transparent Conflict of Interest Disclosure and Management. (2020) (3)
Estramustine phosphate in prostate cancer. EORTC experience: preliminary results of Protocol 30762. (1984) (3)
European Organization for Research and Treatment of Cancer (EORTC) Laboratory Research Division workshop on the role of in vivo pre-clinical models in the development of contemporary cancer therapeutics, Verona, Italy, 3 February 2001. (2005) (3)
The EORTC Central Office/Data Center. (1994) (3)
Ifosfamide plus Adriamycin in Advanced Soft Tissue Sarcomas (1987) (3)
1697 PROGNOSTIC FACTORS AND RISK GROUPS IN T1G3 PATIENTS INITIALLY TREATED WITH BCG: RESULTS OF A MULTICENTER RETROSPECTIVE SERIES IN 2530 PATIENTS (2013) (2)
A Systematic Review of Outcome Reporting, Definition and Measurement Heterogeneity in Non-Muscle Invasive Bladder Cancer Effectiveness Trials of Adjuvant, Prophylactic Treatment After Transurethral Resection (2021) (2)
Response criteria for phase III studies of superficial bladder cancer. (1986) (2)
Currently active protocols in the EORTC Breast Cancer Cooperative Group. (1984) (2)
Analysis and presentation. Clinical trials on prostate cancer. (1997) (2)
Design and analysis of prostate cancer trials. (1994) (2)
Are risk factors for local and distant recurrence following breast-conserving therapy for early breast cancer similar to those following mastectomy? (1998) (2)
Reply from Authors re: R. Houston Thompson. Partial Versus Radical Nephrectomy: The Debate Regarding Renal Function Ends While the Survival Controversy Continues. Eur Urol 2014;65:378–9 (2014) (2)
Serum Alpha-Fetoprotein Surge After the Initiation of Chemotherapy for Non-Seminomatous Testicular Cancer Has an Adverse Prognostic Significance (1999) (2)
A decision theoretic approach to the design of phase II clinical trials in cancer (1984) (2)
Ensuring Consistent European-Wide Urological Care by the Use of Evidence-Based Clinical Practice Guidelines: Can We Do Better (2017) (2)
Statistical Considerations of Chemoprevention Clinical Trials in Prostate Cancer (1999) (2)
T 1 Papillary Carcinoma of the Urinary Bladder : One-Third Dose versus Full Dose and 1 Year versus 3 Years of Maintenance (2013) (2)
948 The impact of different BCG strains on outcome in a large cohort of T1G3 patients treated with BCG (2015) (2)
189 SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH MITOMYCIN C (MMC) AND BACILLUS CALMETTE-GUERIN (BCG) VERSUS BCG ALONE IN PATIENTS WITH CARCINOMA IN SITU (CIS) OF THE URINARY BLADDER. RESULTS OF EORTC GU GROUP RANDOMIZED PHASE II STUDY 30993 (2010) (2)
Radiotherapy plus chemotherapy in muscle-invasive bladder cancer. (2012) (2)
Prognostics factors in previously untreated urothelial cancer patients ineligible for cisplatin-based chemotherapy: An external validation of the Bajorin risk groups. (2013) (2)
Surveillance of stage 1 non-seminomatous testicular cancer: a preliminary report of the EORTC GU-Cooperative Group Surveillance Study (1994) (2)
[Introduction to the statistical aspects of planning clinical oncologic phase III studies]. (1995) (2)
A classified bibliography of controlled trials in perinatal medicine, 1940–1984: Prepared by the National Perinatal Epidemiology Unit, Oxford, England. Oxford Medical Publications, Oxford University Press, Oxford, 1985, 414 pages, $49.95 (1987) (2)
Reply to Donald L. Lamm and Nilay M. Gandhi's letter to the editor re: Behfar Ehdaie, Richard Sylvester, Harry W. Herr. Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol 2013;64:579-85. (2014) (2)
Penalized h‐likelihood approach for variable selection in AFT random‐effect models (2019) (2)
RISK FACTORS FOR RESIDUAL DISEASE AT RE‐TUR IN T1G3 BLADDER CANCER: PD48‐03 (2017) (2)
Fundamentals of clinical trials: L. M. Friedman, C. D. Furberg, and D. L. De Mets John Wright, PSG Inc, Littleton, Massachusetts 1981, 225 pages, $24.50 (1982) (2)
Breastfeeding and breast cancer risk by receptor status — a systematic review andmeta-analysis (2015) (2)
The Role of Fluorescence in Situ Hybridization for Predicting Recurrence after Adjuvant Bacillus Calmette-Guérin in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer Patients: A Systematic Review and Meta-Analysis of Individual Patient Data. (2020) (2)
Oncological outcomes of laparoscopic nephroureterectomy versus open radical nephroureterectomy for upper tract urothelial carcinoma: An European Association of Urology Guidelines systematic review (2018) (2)
O-30 Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials (2003) (2)
PD17-11 THE IMPACT OF DIFFERENT BCG STRAINS ON OUTCOME IN A LARGE COHORT OF T1G3 PATIENTS TREATED WITH BCG. (2015) (2)
Preferential attack on cancer following major cancer surgery. (1971) (2)
4′Deoxydoxorubicin in advanced renal cancer (1986) (2)
Diagnostic and Prognostic Factors in Non-Muscle-Invasive Bladder Cancer and Their Influence on Treatment and Outcomes ☆ (2008) (2)
An introduction to the statistical design of phase III cancer clinical trials. (1997) (2)
Statistical Principles: Myths or Facts? (2003) (2)
A randomized trial comparing the effect of epirubicin and doxorubicin in soft tissue sarcoma (1987) (2)
Prognostic factor analysis from EORTC trials in advanced prostatic cancer. EORTC-GU Group. (1990) (2)
Orchidectomy Versus Total Androgen Blockade. A Phase III Eortc 30853 Study (1990) (2)
Effects of selected sulfhydryl inhibitors on nonhistone chromosomal proteins of HeLa cells. (1975) (1)
Anticipatory effects of ADXBLADDER test results in the follow up of cystoscopy negative non muscle invasive bladder cancer patients in a large multicentric European cohort (2021) (1)
The chemotherapy of advanced bladder cancer (2004) (1)
Mitozolomide in advanced renal cancer. A phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group. (1989) (1)
Establishing minimal institutional patient entry rate requirements for participation in multicenter clinical trials (1980) (1)
Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, non-invasive bladder tumors in 2019? (2019) (1)
A bayesian approach to sample size determination in phase II cancer clinical trials (1984) (1)
Coordinated surgical and drug treatment of cancer. (1976) (1)
582 CMF versus CMF + tamoxifen in advanced breast cancer. Final analysis of a randomized eortc study (1983) (1)
Quality control for storage and transportation of breast cancer samples for the assessment of their estrogen receptor content. (1985) (1)
Altered fractionated radiotherapy in head and neck cancer – Authors' reply (2006) (1)
Preliminary results of phase III study of mitomycin C versus estramustine in progressive metastatic prostate cancer refractory to hormonal therapy — results of EORTC GU group study no. 30865 (1990) (1)
Cochrane cancer network (1995) (1)
PROGNOSTIC FACTORS IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STAGE Ta T1 PAPILLARY CARCINOMA OF THE BLADDER TREATED WITH MAINTENANCE EPIRUBICIN OR MAINTENANCE BACILLUS CALMETTE-GUERIN. RESULTS OF EORTC GU GROUP STUDY 30911 (2008) (1)
Analysis of Clinical Trial Data (1987) (1)
Re: A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences: I. Berrum-svennung, T. Granfors, S. Jahnson, H. Boman and S. Holmang. J Urol 2008; 179: 101-106. (2008) (1)
569 Treatment of advanced breast cancer with medroxyprogesterone acetate: A randomized evaluation of the dose-response relationship at two-dose levels. A phase III trial (1983) (1)
Prognostic performance and reproducibility of the 1973 and 2004/2016 WHO grading classification systems in non-muscle-invasive bladder cancer: A European Association of Urology non-muscle invasive bladder cancer guidelines panel systematic review (2018) (1)
Is there an optimal treatment scheme for adjuvant intravesical therapy? Preliminary analysis of an EORTC protocol comparing early and delayed instillation with and without maintenance of either adriamycin or mitomycin-C in patients with superficial transitional carcinoma of the bladder. (1988) (1)
Predictive assays on individual human cancers to select active drug treatment. (1978) (1)
Standardization in pathologic assessment of transitional cell cancer of the bladder. (1998) (1)
939 Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection to transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder (2015) (1)
1665 BACILLUS CALMETTE-GUERIN ONE THIRD DOSE VERSUS FULL DOSE AND ONE YEAR VERSUS THREE YEARS OF MAINTENANCE. FINAL RESULTS OF EORTC GU CANCERS GROUP RANDOMIZED TRIAL 30962 IN NON MUSCLE INVASIVE BLADDER CANCER (2012) (1)
50 years of the EORTC and the central role of the EORTC Headquarters (2012) (1)
Randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs. estramustine alone in patients with hormone escaped prostate cancer (1999) (1)
4'Deoxydoxorubicin in advanced renal cancer. A phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group. (1986) (1)
Re: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762. (1988) (1)
Prognostic value of the 1973 and 2004/2016 WHO grading systems in primary Ta/T1 non-muscle invasive urothelial carcinoma of the bladder: A multicenter EAU NMIBC guidelines panel study (2019) (1)
Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum. (2022) (1)
Risk tables for predicting progression using the 1973 and 2004/2016 WHO grading classification systems in primary Ta/T1 non-muscle invasive urothelial carcinoma of the bladder: A multicenter EAU NMIBC guidelines panel study (2020) (1)
Comparative study of intravesical instillation of epirubicin, BCG, or BCG + INH in intermediate and high risk pTa-pT1 papillary carcinoma of the urinary bladder. First results of EORTC 30911 (1997) (1)
IL7 EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder : An Update (2010) (1)
進行性尿路上皮癌(UC)患者(pts)におけるゲムシタビン/カルボプラチン(GC)とメトトレキサート/カルボプラチン/ビンブラスチン(M-CAVI)を比較する無作為化第2/3相試験は,シスプラチンに基づいた化学療法(CHT)に適さない:EORTC30986第3相試験の結果 (2010) (1)
Prostatitis and Urethritis (1999) (1)
Preferential inhibition of tumors by drug depressing DNA polymerases. (1971) (1)
Standardized objective criteria of response--comments on 'Important Prognostic Value of Standardized Objective Criteria of Response in Stage D2 Prostatic Carcinoma' by Labrie F. et al. (1989) (1)
The dawn of chemotherapy. Further reflections. (1999) (1)
Rebuttal from Authors re: Guido Dalbagni. Is Intravesical Bacillus Calmette-Guérin Better than Mitomycin for Intermediate-Risk Bladder Cancer? Eur Urol 2009; 56:257―8 (2009) (1)
Response to chemotherapy predicts longer survival in an individual patient meta-analysis of 1205 patients with mesothelioma (2009) (1)
Vol. 35, 1999 (1999) (0)
Progression of Superficial Bladder Tumours 1843 (2017) (0)
Cancer chemotherapy aimed at potential cell regulators. (1969) (0)
Identifying patients with ahighrisk ofrelapse in quiescent Crohn's disease (1995) (0)
Analysis of breast cancer survival by clinical response to neoadjuvant chemoendocrine therapy. (2006) (0)
The EORTC Genito-Urinary Cancers Group: 35 years of achievements and future strategy (2012) (0)
Subject Index Vol. 35, 1999 (1999) (0)
1186 RENAL FUNCTION AFTER NEPHRON-SPARING SURGERY VS. RADICAL NEPHRECTOMY: DATA FROM THE EORTC TRIAL 30904 (2013) (0)
THE DESIGN OF CLINICAL TRIALS FOR NEW THERAPIES IN BLADDER CANCER. IS IT TIME FOR NEW STRATEGIES ? (1995) (0)
A randomized phase II study comparing aminoglutethimide vs. trilostane vs. MPA vs. hydrocortisone: An E.O.R.T.C. study (1986) (0)
Prognostic factors and risk groups in T1G3 patients initially treated with BCG: Results of a multicenter retrospective series in 1743 patients (2013) (0)
An individual patient data (IPD) prognostic factor study on the value of pathological factors in clinical stage I seminoma testis patients under active surveillance from the EAU Testicular Cancer Guidelines panel (2020) (0)
Preliminary trends of the EORTC study comparing postoperative chemotherapy, immunotherapy, chemoimmunotherapy or abstention in squamous cell bronchial carcinoma. (1978) (0)
– Bladder Cancer Repeat Transurethral Resection in Non – muscle-invasive Bladder Cancer : A Systematic Review (2018) (0)
A single immediate instillation of chemotherapy for non-muscle invasive bladder cancer: in all patients? (2018) (0)
[The contribution of estrogen receptors in the therapeutic strategy of breast cancer]. (1981) (0)
How to resolve discrepancies when findings from randomized controlled trials and meta-analyses disagree? (2018) (0)
What is the prognostic importance of urothelial and non-urothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle-invasive and metastatic bladder cancer? Systematic review (2020) (0)
– Bladder Cancer EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder (2008) (0)
PD03-05 DIAGNOSTIC PERFORMANCE OF MCM5 IN THE DIAGNOSIS OF RECURRENT BLADDER CANCER: RESULTS FROM A LARGE PROSPECTIVE, BLINDED, MULTICENTRIC EUROPEAN STUDY (2020) (0)
Comparison of performance of ADXBLADDER with urine cytology in NMIBC follow up: a blinded prospective multicentric study (2020) (0)
Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients. (2021) (0)
European Association of Urology (EAU) Testicular Cancer Guidelines Panel: A new prognostic factor risk group classification for patients with clinical stage 1 seminoma in active surveillance. (2023) (0)
TCNU in advanced renal cancer. Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group. (1989) (0)
A "CONSORT'd" Effort to Improve the Reporting of Urological Randomized Controlled Trials. (2016) (0)
International opinions on grading of urothelial carcinoma: A survey among European Association of Urology and International Society of Urological Pathology members (2023) (0)
Diagnostic performance of MCM5 testing in the diagnosis of recurrent bladder cancer: results from a large prospective, blinded, multicentric european study (2020) (0)
POD-7.08: Intravesical Mitomycin C Versus Bacillus Calmette-Guérin for Non-muscle Invasive Bladder Cancer: An Individual Patient Data Meta-analysis of Randomized Studies (2008) (0)
The three-month recurrence as a prognostic factor for the long term outcome in TaT1 bladder cancer (1999) (0)
Survival analysis: Rupert G. Miller, Jr. New York: Wiley, 1981, 238 pages, $22.00 (1985) (0)
Re: The Result of the Meta-analysis Depends on the Statistical Test Used: Clinical Implication is Important. (2020) (0)
BOOK REVIEW: Clinical Trials Dictionary: Terminology and Usage Recommendations. Curtis L. Meinert, The John Hopkins Center for Clinical Trials, Maryland, 1996. No. of pages: cviii+363. Price: $95. ISBN: 0‐9646424‐0‐9 (1997) (0)
The Correlation Between Grading and Clinical Response (1983) (0)
03 Surrogate endpoints for the prophylactic treatment of tat1 bladder cancer: A combined analysis of eortc and mrc randomized clinical trials (1997) (0)
Re: Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar, Alexandre Mottrie, Riccardo Autorino. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol. 2017;71:606-17. (2017) (0)
655 LONG TERM RESULTS OF THE INTERNATIONAL PHASE III TRIAL BA06 (MRC) 30894 (EORTC) ASSESSING NEO-ADJUVANT CMV CHEMOTHERAPY FOR MUSCLE INVASIVE BLADDER CANCER (2011) (0)
The ef fi cacy of BCG TICE and BCG Connaught in a cohort of 2 , 099 patients with T 1 G 3 non – muscle-invasive bladder cancer (2016) (0)
Do current definitions of BCG failure/ BCG unresponsive NMIBCs correlate with disease progression? Results of an individual patient data validation international multi-center retrospective study (2023) (0)
CLINICAL CANCER CHEMOTHERAPY WITH DRUGS AIMED AT GENE REGULATORS (1976) (0)
Standardization of protocol format. (1986) (0)
RandomizedPhaseIIIStudyComparingPaclitaxel/Cisplatin/ GemcitabineandGemcitabine/CisplatininPatientsWithLocally AdvancedorMetastaticUrothelialCancerWithoutPriorSystemic Therapy:EORTCIntergroupStudy30987 (2012) (0)
Re: Bladder Preservation Multimodality Therapy as an Alternative to Radical Cystectomy for Treatment of Muscle Invasive Bladder Cancer (2011) (0)
Contents, Vol. 26, 1972 (1972) (0)
253 PROGNOSTIC FACTORS OF CANCER RECURRENCE AND PROGRESSION IN PATIENTS WITH NON-MUSCLE-INVASIVE UROTHELIAL CARCINOMA (2011) (0)
Treatment of Ta, T1 Bladder Tumors: Recent Results of the EORTC-GU Group (1998) (0)
Reducing the frequency of follow up cystoscopies for recurrence through the utilization of the urinary biomarker test ADXBLADDER in patients with Low grade, Low stage non-muscle invasive bladder cancer (2021) (0)
Retirement of Professor Maurice J. Staquet (1991) (0)
Estrogen receptors and distribution of prognostic factors in primary breast cancer. (1984) (0)
Contents, Vol. 21, Supplement 1, 1981 (1981) (0)
Contents, Vol. 32, 1975 (1970) (0)
LONG-TERM EFFICACY RESULTS OF EORTC GU GROUP STUDY 30911 COMPARING EPIRUBICIN, BACILLUS CALMETTE- GUERIN (BCG), AND BCG PLUS ISONIAZID IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STAGE Ta T1 BLADDER CARCINOMA (2008) (0)
997 EORTC nomograms for predicting recurrence, progression, overall and disease specific survival in non-muscle invasive Ta T1 bladder cancer patients treated with maintenance Bacillus Calmette-Guerin (2014) (0)
Basic principles of clinical trials as applied to testicular cancer. (1990) (0)
Re-Tur + BCG vs. upfront BCG in high-risk non-muscle invasive bladder cancer: Rationale for a feasibility phase of a randomized controlled study (2021) (0)
How Good Are We at Predicting Outcomes in Non-Muscle Invasive Bladder Cancer? (2018) (0)
Does it matter where you are treated? A treatment outcome study based on clinical trial data (2003) (0)
On the Methodology of Controlled Clinical Trials (1983) (0)
T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum. (2022) (0)
1474 SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH MITOMYCIN C (MMC) AND BACILLUS CALMETTE-GUERIN (BCG) VERSUS BCG ALONE IN PATIENTS WITH CARCINOMA IN SITU (CIS) OF THE URINARY BLADDER. RESULTS OF EORTC GU GROUP RANDOMIZED PHASE II STUDY 30993 (2010) (0)
Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients. (2021) (0)
1694 SIDE EFFECTS OF BCG IN THE TREATMENT OF INTERMEDIATE AND HIGH RISK TA T1 PAPILLARY CARCINOMA OF THE BLADDER: RESULTS FROM EORTC GU CANCERS GROUP RANDOMIZED STUDY 30962 COMPARING 1/3 DOSE VS FULL DOSE DURING 1 OR 3 YEARS (2013) (0)
RE-TUR + BCG vs. upfront BCG in high-risk non-muscle invasive bladder cancer: A feasibility phase of a randomized controlled study (2022) (0)
Congenital Urine Flow Impairments of the Upper Urinary Tract (1999) (0)
Perioperative instillation of chemotherapeutic drugs (2008) (0)
Recurrence and progression according to stage at re-TUR in t1g3 bladder cancer patients treated with BCG: Not as bad as previously thought (2017) (0)
866Bacillus calmette-guerin versus chemotherapy in thi intravesical treatment of carcinoma in situ: A meta analysis of the published results of randomized clinical trials (2005) (0)
TUR only versus epirubicine in single primary or recurrent Ta Tl bladder tumors. EORTC study 30863 (1991) (0)
708 Side effects of BCG in the treatment of intermediate and high risk Ta T1 papillary carcinoma of the bladder: Results from EORTC GU Cancers Group randomized study 30962 comparing 1/3 dose vs full dose during 1 or 3 years (2013) (0)
833PINTERNATIONAL GUIDELINES FOR THE DEFINITION OF TIME TO EVENT ENDPOINTS (TEE) IN RENAL CELL CANCER (RCC) RANDOMISED CLINICAL TRIALS (RCT): RESULTS OF THE DATECAN PROJECT. (2014) (0)
Clinical cancer chemotherapy aimed at cellular control mechanisms. (1970) (0)
The Monitoring and Reporting of Clinical Trials (1995) (0)
Sensitivity tests on human cancers to select active drugs for clinical cancer therapy. (1973) (0)
659 EFFECT OF AGE ON TREATMENT OUTCOME AND TOLERANCE IN PATIENTS WITH STAGE TA T1 PAPILLARY CARCINOMA OF THE BLADDER TREATED WITH MAINTENANCE BACILLUS CALMETTEGUERIN: RESULTS OF EORTC GU GROUP STUDY 30911 (2009) (0)
Interview with Dr Richard Sylvester: transition cell carcinoma of the bladder. Interview by Christine McKillop. (2007) (0)
The updated EAU prognostic factor risk groups overestimate the risk of progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin (2022) (0)
The history of the EORTC GU Group (2010) (0)
[Which intravesical chemotherapy for what tumor of the bladder?]. (1988) (0)
P80 Identifying the types of missingness in longitudinal quality of life data from clinical trials (1997) (0)
RECURRENCE AND PROGRESSION ACCORDING TO STAGE AT RE‐TUR IN T1G3 BLADDER CANCER PATIENTS TREATED WITH BCG: NOT AS BAD AS PREVIOUSLY THOUGHT: PD48‐07 (2017) (0)
Analysis of biological variables in Crohn's disease - Reply (1996) (0)
Study of diamminedichlorocisplatinum in advanced soft tissue sarcoma (protocol 62781) (1978) (0)
– Urothelial Cancer Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma : A Systematic Review by the European Association of Urology Guidelines Panel on Non – muscle-invasive Bladder Cancer (2017) (0)
Subject Index Vol. 36, 1999 (1999) (0)
Evaluation of ADXBLADDER and cytology performance in the follow up of NMIBC: A blinded prospective multicentric study (2020) (0)
Assessing the impact of BCG on progression of NMIBC in the new EAU high risk and very high-risk groups (2022) (0)
Erratum to "European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel" [Eur. Urol. 79(4) (2021) 480-488]. (2023) (0)
A systematic review of heterogeneity in outcome definition and reporting in Non-Muscle Invasive Bladder Cancer (NMIBC) effectiveness trials of adjuvant treatment after transurethral resection (2020) (0)
[The urological group of the EORTC (European Organization for Research on the Treatment of Cancer), 1976-1984]. (1984) (0)
MP56-16 THE IMPACT OF RE-TUR ON CLINICAL OUTCOMES IN A LARGE COHORT OF T1G3 PATIENTS TREATED WITH BCG. (2014) (0)
Comment on: A Single Instillation of Epirubicin After Transurethral Resection of Bladder Tumors Prevents Only Small Recurrences. Authors' reply (2008) (0)
The EORTC Phase III trials in prostatic cancer. (1985) (0)
885 Cochrane cancer network (1995) (0)
Reply (1996) (0)
ZoladexR and flutamide versus bilateral orchiectomy: A randomized phase III trial 30853 study (1990) (0)
Sensitivity tests on individual human cancers to pick active drug therapy. (1974) (0)
TCNU in advanced renal cancer (1989) (0)
Reply from Authors re: Marko Babjuk. New Insights in Intravesical Treatment for Intermediate- and High-Risk Non–Muscle-Invasive Urothelial Bladder Carcinoma. Eur Urol 2010;57:774–6 (2010) (0)
New computer programs for the analysis of clinical trial data (1979) (0)
Study of cis-diammine-dichloro-platinum in advanced soft tissue sarcoma. Protocol 62781, March 1978. (1978) (0)
What are core outcome sets, how should they be developed and why are they essential for urology? (2018) (0)
The efficacy of BCG Tice and BCG Connaught in a cohort of 2099 T1G3 non-muscle invasive bladder cancer patients (2017) (0)
Hyperfractionated or accelerated radiotherapy in head and neck cancer : a fractional benefit? Commentary : a meta-analysis. Commentary (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Richard J. Sylvester?

Richard J. Sylvester is affiliated with the following schools:

Richard J. Sylvester's Academic­Influence.com Rankings

Why Is Richard J. Sylvester Influential?

Richard J. Sylvester's Published Works

Published Works

What Schools Are Affiliated With Richard J. Sylvester?

Richard J. Sylvester's AcademicInfluence.com Rankings